首页> 美国卫生研究院文献>Cancer Science >Drug screening and grouping by sensitivity with a panel of primary cultured cancer spheroids derived from endometrial cancer
【2h】

Drug screening and grouping by sensitivity with a panel of primary cultured cancer spheroids derived from endometrial cancer

机译:使用一组源自子宫内膜癌的原代培养的癌症球体进行敏感性筛选和分组

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Several molecular targeting drugs are being evaluated for endometrial cancer; selecting patients whose cancers are sensitive to these agents is of paramount importance. Previously, we developed the cancer tissue‐originated spheroid method for primary cancer cells taken from patients’ tumors as well as patient‐derived xenografts. In this study, we successfully prepared and cultured cancer tissue‐originated spheroids from endometrial cancers. Characteristics of the original tumors were well retained in cancer tissue‐originated spheroids including morphology and expression of p53 or neuroendocrine markers. We screened 79 molecular targeting drugs using two cancer tissue‐originated spheroid lines derived from endometrioid adenocarcinoma grade 3 and serous adenocarcinoma. Among several hits, we focused on everolimus, a mammalian target of rapamycin complex 1 inhibitor, and YM155, a survivin inhibitor. When sensitivity to everolimus or YM155 was assessed in 12 or 11 cancer tissue‐originated spheroids, respectively, from different endometrial cancer patients, the sensitivity varied substantially. The cancer tissue‐originated spheroids sensitive to everolimus showed remarkable suppression of proliferation. The phosphorylation status of the mammalian target of rapamycin complex 1 downstream molecules before and after everolimus treatment did not predict the effect of the drug. In contrast, the cancer tissue‐originated spheroids sensitive to YM155 showed remarkable cell death. The effect of YM155 was also confirmed in vivo. The histological type correlated with YM155 sensitivity; non‐endometrioid adenocarcinomas were sensitive and endometrioid adenocarcinomas were resistant. Non‐canonical autophagic cell death was the most likely cause of cell death in a sensitive cancer tissue‐originated spheroid. Thus, sensitivity assays using cancer tissue‐originated spheroids from endometrial cancers may be useful for screening drugs and finding biomarkers.
机译:目前正在评估几种分子靶向药物治疗子宫内膜癌的方法。选择对这些药物敏感的癌症患者至关重要。以前,我们开发了针对源自患者肿瘤以及源自患者的异种移植物的原代癌细胞的癌组织起源球体法。在这项研究中,我们成功地制备和培养了来自子宫内膜癌的癌组织起源的球体。原始肿瘤的特征在癌症组织起源的球体中得到了很好的保留,包括形态和p53或神经内分泌标志物的表达。我们使用源自3种子宫内膜样腺癌和浆液性腺癌的两种癌组织起源的球状体筛选了79种分子靶向药物。在一些热门案例中,我们的重点是雷帕霉素复合物1抑制剂的哺乳动物靶点依维莫司和存活蛋白抑制剂YM155。当分别对来自不同子宫内膜癌患者的12或11种癌症组织起源的球体对依维莫司或YM155的敏感性进行评估时,敏感性差异很大。癌症组织起源的球体对依维莫司敏感,显示出明显的增殖抑制作用。依维莫司治疗前后,雷帕霉素复合物1下游分子的哺乳动物靶标的磷酸化状态不能预测药物的作用。相比之下,对YM155敏感的癌组织起源的球体则表现出明显的细胞死亡。在体内也证实了YM155的作用。组织学类型与YM155敏感性相关。非子宫内膜样腺癌敏感,子宫内膜样腺癌耐药。非典型自噬细胞死亡是敏感的癌症组织起源的球体中最有可能导致细胞死亡的原因。因此,使用来自子宫内膜癌的癌组织起源的球体进行敏感性测定可能对筛选药物和寻找生物标志物有用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号